Facebook Twitter LinkedIn
TemasTIOTemas Resources
March 25, 2026

Temas Resources Corp (ASX:TIO): Unique Mineral Processing Technology

Temas Resources is a recently ASX-listed technology and titanium play – joining the ASX in October 2025, but first listed on the Canadian Securities Exchange in 2020. Temas has a potentially breakthrough processing technology (Regenerative Chloride Leach or RCL) that can better recover metals from hard-to-process or complex ore, compared to other approaches. We see […]
Read More
GT3Green360 Technologies
March 24, 2026

Green360 Technologies (ASX:GT3): GT3’s inaugural toll-treatment agreement is signed

Green360 Technologies is a producer of kaolin and is developing a low-carbon cement replacement product known as Eco-Clay. Eco-Clay can replace up to 40% of conventional cement, without compromising the end application’s performance, while significantly reducing carbon emissions of finished concrete. This is achieved by the removal of processes emissions incurred in the burning of […]
Read More
Rhythm Biosciences
March 18, 2026

Rhythm Biosciences (ASX:RHY): ColoSTAT’s rollout is ramping up!

The dream Rhythm Biosciences (ASX:RHY) investors have held ever since the company listed in 2017 has been realised: ColoSTAT has been approved and commercialised, even if slightly different to what investors may have earlier anticipated. The ColoSTAT rollout has begun Rhythm Biosciences completed the first sale of ColoSTAT earlier this month, which represented not only […]
Read More
Prescient Therapeutics
PrescientPTXHealtjhealthbiotech
March 17, 2026

Prescient Therapeutics (ASX:PTX): Ramping up patient enrolment

Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company whose lead asset, PTX-100, is the world’s first-in-class GGTase-1 inhibitor in clinical development — and, as of today, the only drug of its kind targeting relapsed/refractory cutaneous T-Cell Lymphona (CTCL), a very deadly form of cancer. Building a Phase 2 footprint Since our last note, published […]
Read More
February 17, 2026

Rhythm Biosciences (ASX:RHY): ColoSTAT comeback, with Genetype upside

Rhythm Biosciences (ASX:RHY) is a cancer diagnostics company. Since its listing, the Company has been focused on ColoSTAT, a blood test for colorectal cancer. While ColoSTAT is still a focus of Rhythm Biosciences, and the Company is in the early commercialisation phase, the late-2024 acquisition of Genetype could change investor perception entirely. GeneType offers further […]
Read More
ImagionIBXMagSense
February 10, 2026

Imagion Biosystems (ASX:IBX) is preparing for Phase 2

Imagion Biosystems (ASX: IBX) is the company behind MagSense, a revolutionary imaging agent. The company has just made an IND submission to the US FDA and plans to take MagSense into a Phase 2 clinical trial for HER2+ breast cancer once an answer from the regulator is received and this could be as early as Q1 in 2026. A $2bn TAM awaits The market for cancer diagnostics is a US$100bn market. […]
Read More
Register for the Conference